

Republic of the Philippines

PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City
Call Center: (02) 8441-7442 | Trunkline: (02) 8441-7444

www.philhealth.gov.ph



PHILHEALTH CIRCULAR No. 100 LL - 00 S

TO

ALL PHILHEALTH MEMBERS, ACCREDITED HEALTH CARE

PROVIDERS, PHILHEALTH REGIONAL OFFICES, AND ALL

OTHERS CONCERNED

SUBJECT

Modification of Priority Groups for SARS-CoV-2 Testing Packages

Based on the Department of Health (DOH) Guidelines

I. RATIONALE

Entitlement of Phill-lealth beneficiaries to the SARS-CoV-2 Testing packages is based on applicable guidelines set by the DOH and its subsequent issuances.

On January 14, 2022, the DOH issued Department Memorandum (DM) No. 2022-013 titled "Updated Guidelines on Quarantine, Isolation, and Testing for COVID-19 Response and Case Management for the Omicron Variant." This issuance repeals the DOH DM Nos. 2020-0258¹, 2020-0258-A² and 2020-0512³.

II. OBJECTIVES

This policy aims to update the guidelines to:

- A. Align with the updated guidelines and protocols on SARS-CoV-2 testing implemented by the DOH; and
- B. Provide the benefit package for the SARS-CoV-2 testing in diagnosing COVID-19 infection.

II. SCOPE


This PhilHealth Circular (PC) shall apply to PhilHealth beneficiaries tested for SARS-CoV-2 by RT-PCR (cartridge-based or plate-based) as prescribed by the DOH and to DOH-licensed PhilHealth-accredited SARS-CoV-2 testing laboratories.

IV. DEFINITION OF TERMS

A. A1 – refers to frontline workers in health facilities both national and local, private and public, health professionals and non-professionals like students in health and allied professions courses with clinical responsibilities, nursing aides, janitors, barangay health

³ Revised Omnibus Interim Guidelines on Prevention, Detection, Isolation, Treatment, and Reintegration Strategies for COVID-19





¹ Updated Interim Guidelines on Expanded Testing for COVID-19

² Amendment to Department Memorandum No. 2020-0258 entitled Updated Interim Guidelines on Expanded Testing for COVID-19

workers, among others⁴. This includes health care workers and non-health care workers involved in COVID-19 response as defined in Republic Act (RA) No. 11712⁵.

- B. A2 refers to senior citizens/persons aged 60 and above prioritized for SARS-CoV-2 testing.
- C. A3 refers to person with co-morbidities including those at high risk for severe disease prioritized for SARS-CoV-2 testing.
- D. Health care and non-health care workers refer to all public and private medical, allied medical, administrative, technical, support and other necessary personnel employed by, and assigned in hospitals, health facilities, laboratories, medical or temporary treatment and monitoring facilities, or vaccination sites. For COVID-19 pandemic, it also includes those who are involved in COVID-19 response to mitigate transmission and prevent further loss of lives in line with the National Action Plan Against COVID-19 strategy of prevention, detection, isolation, treatment, rehabilitation, and vaccination (PDITR+ Strategy).

V. POLICY STATEMENTS

A. Availment of the Benefit Package

1. PhilHealth shall align the coverage of the SARS-CoV-2 testing benefit package by amending Annex B "Sub-groups of at-risk individuals for SARS-CoV-2 testing" of PhilHealth Circular 2021-0021 entitled "Benefit Packages for SARS-CoV-2 Testing Using RT-PCR Tests (Plate-based and Cartridge-based)" to follow the DOH DM 2022-013 entitled "Updated Guidelines on Quarantine, Isolation, and Testing for COVID-19 Response and Case Management for the Omicron Variant." The subgroups of at-risk individuals A-J based on DOH DM 2020- 258 and 258-A shall no longer prevail, hence, the table below shall be the updated priority groups for testing:



Priority groups	Purpose of SARS-CoV-2 test
A1 – Health Care Workers	For surveillance, to plan health system capacity
A2 – Senior Citizens	
A3 - comorbidities and	Confirming COVID-19 for use of investigational
high risk for severe disease	drugs
All except A1, A2 and A3	Confirming COVID-19 after onset of symptoms
with symptoms of	(optional to test)
COVID-19	

Table 1: Priority groups for SARS-CoV-2 testing

It is emphasized that SARS-CoV-2 testing is NOT recommended for asymptomatic close contacts. Instead, symptom monitoring is recommended. Should testing be used, it should be done at least five (5) days from the last day of exposure. Further, SARS-CoV-2 testing is also NOT recommended for screening asymptomatic individuals.

⁵ Republic Act No 11712 "An Act Granting Mandatory Continuing Benefits And Allowances To Public And Private Health Care Workers During The Covid-19 Pandemic And Other Future Public Health Emergencies, And Appropriating Funds Therefor"



⁴ DOH Administrative Order No. 2022-0005 "Omnibus Guidelines on the Implementation of the National Development and Vaccination Plan (NDVP) for COVID-19 Vaccines".

- 2. Accreditation guidelines for SARS-CoV-2 testing laboratories shall remain in effect as stipulated in Annex A "Application for Accreditation of SARS-CoV-2 Testing Laboratories."
- 3. All testing claims shall be filed through eClaims using the revised versions of Annexes of this PC.
- 4. To file a claim for reimbursement, the accredited testing laboratories shall submit the following documents to PhilHealth:
 - a. Properly accomplished SARS-CoV-2 Claims Summary Form (Annex "C") (preferably in MS Excel format or CSV file):
 - b. Scanned copy of the properly accomplished CIF that is prescribed by the DOH (preferably in PDF format);
 - c. Itemized billing statement, which includes the readers' fees (preferably in MS Excel format or CSV file) which shall be required for admitted patients only;
 - d. Original, photocopy or printed scanned copy (preferably in PDF format), of Annex E: "Certificate of classification of priority groups and actual charges for SARS-CoV-2 test". This form shall also be considered as an equivalent to Statement of Account (SOA) as it contains the actual charges, discounts, and amount of PhilHealth benefits.
- 5. For directly filed claims, the following documents are required:
 - a. Original copy of the official receipt;
 - b. Original, photocopy or printed scanned copy of the Annex D: "Waiver for directly filed claims for SARS-CoV-2 testing package" issued by the PhilHealth-accredited SARS-CoV-2 testing laboratory that the member paid the full amount for the SARS-CoV-2 testing and no Phill-lealth deduction was made. The member shall bear the responsibility of keeping the said copy of the waiver for validation purposes during case investigation or domiciliary monitoring; and
 - c. Original, photocopy, or printed copy of the Case Investigation Form.

B. Monitoring and Evaluation

- 1. All Phill-lealth-accredited facilities with claims for this benefit package shall be subject to the rules on monitoring prescribed by PhilHealth.
- 2. Feedback mechanisms on the package implementation shall be established to address implementation issues and concerns.



C. List of Annexes (May be accessed in the PhilHealth Website)

- 1. Annex A Application for Accreditation of SARS-CoV-2 Testing Laboratories
- 2. Annex B Priority Groups for SARS-CoV-2 Testing

This Annex B Priority Groups for SARS-CoV-2 Testing repeals the previous Annex B "Sub-groups of at-risk individuals for SARS-CoV-2 testing.

- 3. Annex C SARS-CoV-2 Claims Summary Form
- 4. Annex D Waiver for Directly Filed Claims for SARS-CoV-2 Testing Package
- 5. Annex E Certificate of classification of priority groups and actual charges for SARS-CoV-2 Test

VI. PENALTY CLAUSE

Any violation of this PhilHealth Circular shall be dealt with and penalized in accordance with the pertinent provisions of RA No. 11223 and RA No. 7875, as amended by RA Nos. 9241 and 10606, and their respective Implementing Rules and Regulations.

VII. TRANSITORY CLAUSE

- A. All claims with specimen collection dates prior to the effectivity of this PhilHealth Circular shall follow PC No. 2021-0021 titled "Benefit Packages For SARS-CoV-2 Testing Using RT-PCR Tests (Plate-based and Cartridge-based)";
- B. All claims with specimen collection dates beginning from the date of publication shall follow the forms as prescribed in this PhilHealth Circular.

VIII. SEPARABILITY CLAUSE

If any provision of this PhilHealth Circular shall be declared invalid, unconstitutional, or unenforceable, the validity of the remaining provisions shall not in any way be affected and shall remain enforceable.

REPEALING CLAUSE

This Phill-lealth Circular repeals Section V.B.1 of PC No. 2021-0021. All other issuances that are inconsistent with this Phill-lealth Circular are hereby modified, amended, and repealed accordingly.





Page 4 of 5

X. DATE OF EFFECTIVITY

This PhilHealth Circular shall take effect immediately upon publication in any newspaper of general circulation or in the Official Gazette. A copy of this PhilHealth Circular shall thereafter be deposited at the Office of the National Administrative Register (ONAR) of the University of the Philippines Law Center.

ATTY. ELI DINO D. SANTOS,
Officer-in-Charge, Office of the President and CEO



Modification on Priority Groups for SARS-CoV-2 Testing Packages Based on Department of Health (DOH)



Page 5 of 5

Annex A: Guidelines on the Application for Accreditation of SARS-CoV-2 Testing Laboratories

Guidelines on the Application for Accreditation of SARS-CoV-2 Testing Laboratories

- 1. All currently accredited health facilities with valid DOH license for SARS-CoV-2 testing laboratory do not need to apply for accreditation. PhilHealth shall automatically include the said service in their accreditation records with validity starting on the date that the DOH granted its license. Accredited testing laboratory for SARS-CoV-2 in currently accredited health facility shall submit a fully accomplished Auto Credit Payment System (ACPS) form ONLY IF payment for the laboratory benefit shall be separate from regular claims of the accredited health facility.
- 2. Requirements for non-hospital-based testing laboratory for SARS-CoV-2 or laboratory of a non-accredited health facility:
 - a. A valid DOH license as SARS-COV-2 testing laboratory
 - b. Accomplished Provider Data Record
 - c. Performance Commitment (signed on each page)
 - d. Fully accomplished Auto Credit Payment System (ACPS) form
- 3. All requirements for accreditation of testing laboratories mentioned in No. 2 shall be scanned and emailed to the respective PhilHealth Regional Offices. The Provider Data Record, Performance Commitment, and the ACPS forms can be downloaded at https://www.philhealth.gov.ph/downloads/.

	PRO	Email address	Name				
	1	accre.pro1@philhealth.gov.ph	PRO1- Accreditation				
	2	accre.pro2@philhealth.gov.ph	PRO2 - Accreditation				
	3	accre.pro3@philhealth.gov.ph	PRO3 - Accreditation				
	4A	accre.pro4a@philhealth.gov.ph	PRO4A - Accreditation				
	4B	accre.pro4b@philhealth.gov.ph	accre.pro4b				
	5	accre.pro5@philhealth.gov.ph	PRO5 - Accreditation				
	6	accre.pro6@philhealth.gov.ph	PRO6 - Accreditation				
	7	accre.pro7@philhealth.gov.ph	PRO7 - Accreditation				
	8	accre.pro8@philhealth.gov.ph	PRO8 - Accreditation				
!	9	accre.pro9@philhealth.gov.ph	accre.pro9				
;	10	pro10aqas@gmail.com	Philhealth Accre				
1	11	philhealthdavao.aqas@gmail.com	philhealthdavao.aqas				
$ \cdot $	12	accre.pro12@philhealth.gov.ph	PRO12 - Accreditation				
$ \cdot $		accre.procaraga@philhealth.gov.ph	PROCARAGA - Accreditation				
		accre.proarmm@philhealth.gov.ph	accre.proarmm				
!	CAR	accre.procar@philhealth.gov.ph	PROCAR - Accreditation				
š	NCR	proncr.hcdmd@yahoo.com	PRO NCR HCDMD				

Source: PhilHealth Accreditation Department as of September 22, 2021

4. The validity of accreditation of DOH-licensed stand-alone SARS-CoV-2 laboratories health facilities applying for initial accreditation or reaccreditation due to gap in the previous accreditation shall be from the date of submission of the complete application and ends on December 31 of the current year. Further, the validity of accreditation of health facilities applying for continuous accreditation is from January 1 to December 31 of the current year.

Page 1 of 1 of Annex A

Priority Groups for SARS-CoV-2 Testing

The following reflects the priority groups for SARS-CoV-2 testing:

Priority groups	Purpose of SARS-CoV-2 test
A1 – Health Care	For surveillance, to plan health system capacity
Workers	
A2 – Senior Citizens	
A3 – comorbidities and	Confirming COVID for use of investigational drugs
high risk for severe	
disease	
All except A1, A2 and A3	Confirming COVID after onset of symptoms
with symptoms of	(optional to test)
COVID-19	

Source: Department of Health 2022-013





SARS-CoV-2 CLAIMS SUMMARY FORM

lame of the PhilHe hilHealth Accred			laboratory:		.=-					Address:									
PATIENT INFORMATION MEMBER					INFORMATION	٠		Priority Groups for SARS-CoV-2	Date of		Services					amount arter application of discounts/deduc	Phill-leabh		
To Last name	FinGame	- Name extension	Middle name	Date of birth (mm/dd/yyyy)	PIN	Last name	First name	Name extension	Middle name	Testing (A1, A2, A3, all except A1, A2 and A3)	specimen collection (mm/dd/yyyy)	Date of running the PCR test (mm/dd/yyyy)	covered by PhilHealth (1, 2, 3, 4, 5)	Test result (pos/neg)	Test kit donated (Y/N)	Package code	Total actual charges to patient (Php)	tions (senior citizen persons with disability, guarantee letter,	benefit package amount
1	~~	<u>†</u>																erri	
2	-8	<u> </u>	_	ļ													ļ		
	<u> </u>	 	 	 				 		-							1		
3 05	- 6	-		 				 					-				 		
			1					Ì			,								
7 13							_	 					_						_
	(১৯১							 	 								<u> </u>		
0 2	1-27	 	<u> </u>	+				1										-	
1			 	1				1									 		-
2																			
3	2																		
15	 			 				1	-	 							 		-
Prepared by:	printed name of t	ho authorizad a	ionatory of t	- -	Date signed		Approved by:	_		Signature over	printed name of	the Hand of the					Date signed		
PhilHealth acc	redited SARS-Co	V-2 testing labo	ratory/HCP	ne	Date signed				:	PhilHealth accredited			HCP				Date signed		
	corresponding		s							nte the corresponding "Services covere		1"			the SARS-CoV- olumn "Packag		ackage availe	ed of in the	
, G	s for SARS-CoV	J		,					1 Screeni	covered by PhilHeang ng en collection	ith;			C19T1	ARS-CoV-2 test All services and a are procured and laboratory	supplies for	the testing	C19X1	All services and supplie for the testing are proc- and provided by the tes
Refer to the co	rrent DOH appl	icable testing gu	udelines and	protocols					·						Test kits are don laboratory	ated to the	testing		PCR cartridges are don to the testing laborator
									4 Conduc	en handling et of RT-PCR testing is and reporting of re	ults			C19T2 C19T3	Test kits are don laboratory; cost of laboratory and th	of running t	he	C19X2 C19X3	PCR cartridges are dor to the testing laborate the cost of running t
The information of benefits enhanced Note: Donated to	ent and quality in	aprovement.					ne veracity of the	claims to effe	ect efficient	processing of benefi	payment, Furth	er, informed com	tained herein s	hall be entere	d in the Phili-Healt	h database a	and may be us	ed for policy res	arch,

Instruction in the submission of Itemized Billing Statement for SARS-CoV-2 test for all accredited testing laboratories

- 1. PhilHealth shall assign a username and password to each accredited testing laboratory to access the FTP server. Accredited testing laboratories can request FTP accounts by creating a ticket with subject "UPECS-EMR / Benefit Costing" in the PhilHealth Ticketing System that is accessible through the link: https://itsupport.philhealth.gov.ph/osticket/
- 2. The accredited testing laboratory will receive an email from PhilHealth indicating the user account information containing the username and password, storage folder and the FTP guide.
- 3. Each accredited testing laboratory will be assigned a designated storage folder to upload their claims summary form and itemized billing statement.
- 4. All Excel or csv files should be submitted using the FTP server. In the event of system downtime, accredited testing laboratories should coordinate with their respective Regional Office IT.
- 5. For inquiries and/or clarification related to FTP and account creation, please email upecsemr@philhealth.gov.ph.





[PHILHEALTH ACCREDITED SARS-CoV-2 TESTING LABORATORY/HCP LOGO] SARS-CoV-2 Test Waiver

This waiver (original, photocopy or printed scanned copy) together with other supporting documents should be filed within sixty (60) calendar days from the date of specimen collection for directly filed claims for SARS-CoV-2 testing package.

Date		
To PhilHealth:		
This is to certify that based on our records,		,
This is to certify that based on our records, _	Patient's last name, first name, name e	extension, middle name
who belongs to priority group_ guidelines and protocols, was tested for SAR	based on the current DC S-CoV-2 at	H applicable testing
Name of Phil	Health accredited SARS-CoV-2 testing labor	ratory/HCP ,
on		
On Date/s of	specimen collection (mm/dd/yyyy)	
was charged for the services included in the	• •	
All charges to the amount of		
	Amount in words	
(Php) were full	ly paid by the patient/member unde	r Official Receipt No/s.
reason/s:	Reason/s	
With this waiver, the Name of PhilHealth accredit	ted SARS-CoV-2 testing laboratory/HCP	vill not file reimbursement
from PhilHealth for the benefit package for	SARS-CoV-2 testing.	
This waiver is being issued upon the request	of	name extension, middle name
for whatever legal purpose it may serve.	2 Marie of Florido Co and Family, 1800 Marie	, mille victimion, miller
Signature over printed name of the authorize	ed testing laboratory/HCP represent	tative
Designation of the authorized testing laborat	tory/HCP representative	Date signed
Conforme:		
· · · · · · · · · · · · · · · · · · ·		_
Signature over printed name of the patient/1	member/authorized representative	Date signed

Annex E: Certificate of Classification of Priority Groups and Actual Charges for SARS-Cov-2 Test and Instruction for the Facility

[PHILHEALTH ACCREDITED SARS-CoV-2 TESTING LABORATORY/HCP LOGO]

This certificate (original, photocopy or scanned copy) if accomplished by the swabbing center shall be forwarded to the accredited testing laboratory. The testing laboratory together with other supporting documents should be filed within sixty (60) calendar days from the date of specimen collection for all filed claims for SARS-CoV-2 testing package.

To P	hilHealth:						
This	is to certify that based on ou	r records	s,		_		,
			Patient's	last name, fü	st name, name e	extension,	middle name
	belongs to priority group ocol, was tested SARS-CoV-2		ased on the c	urrent DC)H applicable	testing (guidelines and
at		ć=1.0== .1					,
	Name o	t PhilHeal	th accredited SA	ARS-CoV-2 t	esting laborator	y/HCP	
on_					and incur	red the f	ollowing charges:
	Date/s of specimen	collection	(mm/dd/yyyy)		_		0 0
D1	. a (a) in the	: al., 1					
	e a (✔) in the appropriate t □ No charge to patient	ick dox					
•	I If with actual charges, ind	licata tha	following				
1 1	ir with actual charges, into	ucaic life	tollowing:				
41		Item			<u> </u>	Amour	ıt (Php)
Date:	Total actual charges	-	<u>-</u>				(<u>-</u> <u>-</u>
Ö	Amount after application				r -		
11	citizen persons with disab PhilHealth benefit packag			etc.)	_		
211	Timi icatti belicit paciag	<u>c amour</u>					
2	Official receipt no./s				_		
الئ							
ري			· 1 · · ·	· •	/ * TOD		
Signa	ture over printed name of the	e author	ized testing l	aboratory/	HCP represe	entative	
	·						
Desi	gnation of the authorized tes	ting labo	oratory/HCP	represent	ative		Date signed
Confe	orme:						
Signa	ture over printed name of the	e membe	er/patient/ a	uthorized	renresentativ		Date signed
0	The state of the		Spouse		Child:		Others,
	onship of the		Siblings		Parent		specify
repres	sentative to			•			
	per/patient on for signing on behalf of		Patient is in				
	ree and organize the political OF		T GITTIL IS III	capacitate	u		

